6-[5-((R)-3-acetylamino-pyrrolidin-1-yl)-2-trifluoromethyl-phenyl]-4-(4-fluoro-3-methoxy-phenyl)-7-oxo-2,3,6,7-tetrahydro-pyrrolo[2,3-d]pyridazine-1-carboxylic acid amide | 937192-82-0

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物
• 英文名称: 6-[5-((R)-3-acetylamino-pyrrolidin-1-yl)-2-trifluoromethyl-phenyl]-4-(4-fluoro-3-methoxy-phenyl)-7-oxo-2,3,6,7-tetrahydro-pyrrolo[2,3-d]pyridazine-1-carboxylic acid amide
• 英文别名: 6-[5-[(3R)-3-acetamidopyrrolidin-1-yl]-2-(trifluoromethyl)phenyl]-4-(4-fluoro-3-methoxyphenyl)-7-oxo-2,3-dihydropyrrolo[2,3-d]pyridazine-1-carboxamide
• CAS: 937192-82-0
• 化学式: C₂₇H₂₆F₄N₆O₄
• 分子量: 574.535
• InChiKey: YOGIAMLRSGPMBE-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  41
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• HETEROCYCLIC COMPOUND AND MEDICINAL APPLICATION THEREOF
  申请人：Japan Tobacco, Inc.

  公开号：EP1953147A1

  公开（公告）日：2008-08-06

  The present invention aims at providing a novel heterocyclic compound having HCV entry inhibitory activity and the pharmaceutical use thereof. The present invention provides a therapeutic agent for hepatitis C comprising a heterocyclic compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof as an active ingredient: wherein Q1 is -N=, etc., Q2 is -N-, etc., Q3 is -N=, etc., Q4 is -N-, etc., Q5 is -N-, etc., R1 is a hydrogen atom, etc., R2 is a hydrogen atom, etc., ring A is a monocyclic aryl group optionally having substituent(s), etc., and ring B is a monocyclic aryl group optionally having substituent(s), etc.

  本发明旨在提供一种具有HCV进入抑制活性的新型杂环化合物及其药物用途。本发明提供了一种治疗丙型肝炎的治疗剂，其包括以下式[1]所表示的杂环化合物或其药学上可接受的盐作为活性成分：其中Q1为-N=等，Q2为-N-等，Q3为-N=等，Q4为-N-等，Q5为-N-等，R1为氢原子等，R2为氢原子等，环A为单环芳基，可选地具有取代基等，环B为单环芳基，可选地具有取代基等。